Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove English
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Adolescents as Population Group
- Remove People with Mental Health Problems as Population Group
- Remove Hispanic or Latino
- Remove Racial & Ethnic Groups
- Remove Opioids or Opiates
- Remove Cocaine
- Remove Illicit Stimulants
- Remove Fentanyl
- Remove Inhalants
Main page content
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: July 2020
This issue brief presents recent data on prevalence of opioid misuse & death rates in the Hispanic/Latino population; contextual factors & challenges to prevention & treatment; innovative outreach & engagement strategies to connect people to evidence-based treatment; and the importance of community voice.
Published: March 2020
This fact sheet for teens provides facts about stimulants. It describes short- and long-term effects, lists signs of use, and helps dispel common myths. It also can be used by prevention professionals, educators, health care providers, and others who come in contact with teens on a regular basis.